Recurrent Squamous Cell Lung Carcinoma Active Not Recruiting Phase 2 Trials for Telisotuzumab vedotin (DB15104)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03574753Lung-MAP S1400K: c-MET PositiveTreatment